MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia

Haematologica

Volumn 96, Issue 5, 2011, Pages 703-711

  Schotte, Diana ^a   de Menezes, Renée X ^a,b   Moqadam, Farhad Akbari ^a   Khankahdani, Leila Mohammadi ^a   Lange Turenhout, Ellen ^a   Chen, Caifu ^c   Pieters, Rob ^a   den Boer, Monique L ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c APPLIED BIOSYSTEMS   (United States)

Author keywords

Drug resistance; Genetic subtype; Mirna; Pediatric leukemia; Prognosis

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; DAUNORUBICIN; MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 99A; MYC PROTEIN; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CLASSIFICATION; CHILD; CONTROLLED STUDY; DIPLOIDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG RESISTANCE; GENE; GENETIC VARIABILITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LET 7B GENE; MAJOR CLINICAL STUDY; PRE B LYMPHOCYTE; PROGNOSIS; UPREGULATION;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CLUSTER ANALYSIS; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENETIC VARIATION; HUMANS; MICRORNAS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; VINCRISTINE;

EID: 79955716719     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.026138     Document Type: Article

References (44)

1. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105.
2. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11(3):228-234.
3. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2): 215-33.
4. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303 (5654):83-6.
5. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19):4586-94.
6. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102 (39):13944-9.
7. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043): 828-33.
8. Meijerink JP, den Boer ML, Pieters R. New genetic abnormalities and treatment response in acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):16-23.
9. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998-1006.
10. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007; 370(9583):240-50.
11. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Korholz D, et al. Patient stratification based on prednisolone- vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21 (17):3262-8.
12. Hongo T, Yajima S, Sakurai M, Horikoshi Y, Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2959-65.
13. Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van Wering ER, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997;90(7): 2723-9.
14. Pieters R, Huismans DR, Loonen AH, Hahlen K, Van der Does-van den Berg A, van Wering ER, et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991;338(8764):399-403.
15. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, et al. Targeting FLT3 in primary MLL-generearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484-90.
16. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, et al. Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(2):313-22.
17. Weerkamp F, de Haas EF, Naber BA, Comans-Bitter WM, Bogers AJ, van Dongen JJ, et al. Age-related changes in the cellular composition of the thymus in children. J Allergy Clin Immunol. 2005;115 (4):834-40.
18. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood. 1990;76(11):2327-36.
19. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RTPCR. Nucleic Acids Res. 2005;33(20):e179.
20. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2): 125-34.
21. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20(16): 1981-9.
22. Petricoin EF, 3rd, Espina V, Araujo RP, Midura B, Yeung C, Wan X, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67(7):3431-40.
23. Zuurbier L, Homminga I, Calvert V, Tewinkel ML, Buijs-Gladdines JG, Kooi C, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014-22.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. JRSS B. 1995;57(1):289-300.
25. Team RDC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org 2008.
26. Pollard KS, Dudoit S, van der Laan M. Multiple Testing Procedures: R multtest Package and Applications to Genomics in Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer (Statistics for Biology and Health Series). 2005;251-72.
27. Raimondi SC, Pui CH, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996;10(2): 213-24.
28. Stam RW, Schneider P, Hagelstein JA, Van der Linden MH, Stumpel DJ, de Menezes RX, et al. Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood. 2010;115(14):2835-44.
29. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-43.
30. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102(8):2951-9.
31. Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, et al. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009;113(14):3314-22.
32. Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, et al. Expression of miR-196b is not exclusively MLL-driven but especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 2010:95(10):1675-82.
33. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA. 2008;105(40):15535-40.
34. Holleman A, Cheok MH, den Boer ML, Yang W, Veerman AJ, Kazemier KM, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351(6):533-42.
35. Lugthart S, Cheok MH, den Boer ML, Yang W, Holleman A, Cheng C, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005; 7(4):375-86.
36. Gefen N, Binder V, Zaliova M, Linka Y, Morrow M, Novosel A, et al. Hsa-mir- 125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53. Leukemia. 2010;24(1):89-96.
37. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, et al. Myeloid cell differentiation arrest by miR- 125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205(11):2499-506.
38. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, et al. Mir-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev. 2010;24(5):478-90.
39. Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, et al. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009;4(11): e7826.
40. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007;67 (22):10782-8.
41. Agirre X, Jimenez-Velasco A, San Jose Eneriz E, Garate L, Bandres E, Cordeu L, et al. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008;6(12):1830-40.
42. Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009;61(11):1075-82.
43. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 5(1):e8960.
44. Stumpel DJM, Schotte D, Lange-Turenhout EA, Schneider P, Seslija L, De Menezes RX, et al. Hypermethylation of specific miRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at microscale. Leukemia 2011;25(3):429-39.